Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Summary
Trastuzumab deruxtecan (T-DXD) as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. This study will assess the effectiveness of T-DXd, patient demographic and clinical characteristics, and treatment patterns in patients with advanced HER2-positive advanced gastric or GEJ adenocarcinoma.
Official title: A Prospective Non-interventional Study (NIS) of Trastuzumab DeRuxtecan (T-DXd) for Adult Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction (GEJ) AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen, Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies in a Real-world Setting in Europe (PROSPERITY)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
257
Start Date
2023-12-05
Completion Date
2027-09-01
Last Updated
2026-08-20
Healthy Volunteers
No
Conditions
Interventions
Trastuzumab deruxtecan
This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice. T-DXd to be administered according to the SmPC. Conventional therapy (eg. platinum-fluoropyrimidine doublet chemotherapy, nivolumab, ramucirumab-paclitaxel, ramucirumab monotherapy, taxane or irinotecan, and pembrolizumab monotherapy) to be administered according to the SmPC.
Locations (39)
Ordensklinikum Linz GmbH Barmherzige Schwestern
Linz, Austria
Medizinische Universität Wien
Vienna, Austria
Kepler Universitätsklinikum
Wels, Austria
Landesklinikum Wiener Neustadt
Wiener Neustadt, Austria
Krankenhaus St. Vinzenz in Zams
Zams, Austria
OLV Hospital Aalst
Aalst, Belgium
Antwerp University Hospital
Edegem, Belgium
UZ Gent
Ghent, Belgium
CHU Helora Hospital de La Louvière - Site Jolimont
Haine-Saint-Paul, Belgium
JESSA Hasselt
Hasselt, Belgium
UZ Brussel
Jette, Belgium
MVZ am Klinikum Aschaffenburg
Aschaffenburg, Germany
Vivantes Klinikum im Friedrichshain
Berlin, Germany
Charite Campus Benjamin Franklin
Berlin, Germany
MV-Zentrum für Hämatologie & Onkologie
Cologne, Germany
University Hospital Essen
Essen, Germany
Alb Fils Kliniken GmbH
Göppingen, Germany
Hämatologisch-Onkologische Praxis Eppendorf (HOPE)
Hamburg, Germany
Studienzentrum am Raschplatz GbR
Hanover, Germany
KRH Klinikum Siloah
Hanover, Germany
Gemeinschaftspraxis Dr. Haytham Kamal / Dr. David C. Dorn
Hanover, Germany
Klinikum rechts der Isar der Technischen Universität München
München, Germany
Klinikum am Steinenberg Reutlingen
Reutlingen, Germany
CaritasKlinikum Saarbrücken
Saarbrücken, Germany
Praxis Onkologie Rheinsieg
Troisdorf, Germany
IRCCS "S. De Bellis"
Castellana Grotte, Italy
ARNAS Garibaldi - PO Nesima
Catania, Italy
AOU Careggi
Florence, Italy
IRCCS AOU San Martino
Genova, Italy
IRCCS Ospedale San Raffaele
Milan, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Azienda Ospedaliero-Universitaria di Modena
Modena, Italy
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Naples, Italy
Università degli studi di Napoli Federico II
Naples, Italy
Università della Campania 'Luigi Vanvitelli'
Naples, Italy
AOU Pisana - Stabilimento Santa Chiara
Pisa, Italy
AUSL della Romagna - Ospedale "S. Maria delle Croci" di Ravenna
Ravenna, Italy
Policlinico Universitario Campus Bio-Medico
Roma, Italy
AO "Cardinale Giovanni Panico"
Tricase, Italy